Clinical trials: Other Metabolic Diseases
Cancer, Mental Health
Healthspan Connect Programme of Research
Healthspan Connect is a new research programme designed to understand what helps people stay healthy as they age. The programme will explore how lifestyle, environment, genetics, and social factors influence healthy ageing and…
- Conditions
- Cancer, Mental Health, Ageing Well, Resilience
- Trial name
- NCT07209774
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- King's College London
Schizophrenia, Metabolic Syndrome
The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome
Almost all of antipsychotics can induce metabolic syndrome,Genetic factors play a key role in the development of metabolic syndrome,TCF7L2 and SLC30A8 are strongestly correlated with metabolic syndrome.Moreover,Antipsychotics…
- Trial name
- NCT02093858
- Where
- China
- Volunteers
- 212 people
- Sponsor
- Central South University
Obesity
Situation and Evolution of the Misuse of Alcohol and Other Addictive Behaviors in Obese Patients Being Managed at Nîmes University Hospital
Obesity is a multifactorial pathology in which external (lifestyle, environment) and internal (psychological or biological, especially genetic) factors are involved. These are responsible for a positive energy balance.
- Trial name
- ADOB (NCT04613791)
- Testing
- Blood test
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Genetic Disorder, Asperger Disorder
Pediatric Patients With Metabolic or Other Genetic Disorders
Background: Some patients with unusual genetic conditions are referred to the National Institutes of Health (NIH). They may not be eligible to join current research studies.
- Conditions
- Genetic Disorder, Asperger Disorder, Autism Spectrum Disorder, Fragile X Syndrome
- Trial name
- NCT02769949
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Schizophrenia, Schizoaffective Disorder
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
This study involves people who have schizophrenia or schizoaffective disorder who are currently taking antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00595504
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Vitamin D Deficiency, Vascular Calcification
Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis
Aim: To investigate whether cholecalciferol (4800 U/daily) or placebo for 16 weeks reduces proteins levels associated with vascular calcification (osteoprotegerin, osteopontin, osteocalcin) in patients treated with peritoneal…
- Conditions
- Vitamin D Deficiency, Vascular Calcification, Renal Insufficiency, End Stage Renal Failure on Dialysis
- Trial name
- NCT02598635
- Testing
- Cholecalciferol
- Where
- Mexico
- Volunteers
- 58 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Dyslipidemia
Fluvastatin in Adults With Dislipidemia With History of Muscle Problems
The purpose of the study is to find a good therapy for patients who need to be treated for high cholesterol and who have difficulty tolerating other statins (such as pravastatin, simvastatin, lovastatin, atorvastatin…
- Trial name
- NCT00125125
- Testing
- Fluvastatin
- Where
- 2 sites in United States, Germany
- Volunteers
- 218 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia and Disorders With Psychotic Features
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist…
- Trial name
- NCT00748566
- Testing
- Ziprasidone HCL (oral)
- Where
- 32 sites in Canada
- Volunteers
- 172 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obesity, Type 2 Diabetes Mellitus
A Study to Examine Changes in GIP Plasma Levels Following Gastric Bypass Surgery in Obese Patients
Obesity is a multinational epidemic. There is evidence that despite educational measures and increased public awareness, the number of obese individuals continues to increase.
- Conditions
- Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
- Trial name
- NCT00207389
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Boston Medical Center
Diabetes Mellitus, Schizophrenia
Diabetes Prevention Program in Schizophrenia [DPPS]
Diabetes is 2-5 times more common in schizophrenia and it is a preventable; but the current diabetes prevention guidelines are not suitable for implementation in the severely mentally ill population.
- Trial name
- NCT00182494
- Testing
- Modified diabetes prevention protocol & Metformin
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Hamilton Health Sciences Corporation
Amyloidosis
Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging
The principal aim of this study is to investigate the cardiac uptake of 89Zr-GSK2398852 in subjects with transthyretin cardiomyopathy amyloidosis (ATTR-CM), and its biodistribution to other organs.
- Trial name
- NCT03417830
- Testing
- GSK2315698 (CPHPC), GSK2398852 (unlabeled anti-SAP mAb), 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)
- Where
- Sweden
- Volunteers
- 2 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia
A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting
This was a multicenter, non-randomized, non-interventional three-cohort study with prospective collection of primary data of treatment with newly initiated oral lipid lowering treatment on top of a statin (Oral LLT cohort), newly…
- Trial name
- NCT05362903
- Testing
- Inclisiran
- Where
- 121 sites in Germany
- Volunteers
- 1,868 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT00222807
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Effect of Single Dose Intranasal Insulin On Cognitive Function
The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00646581
- Testing
- Insulin (Humulin)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Preterm Birth, Gestational Diabetes Mellitus (GDM)
Evaluation of Maternal and Neonatal Outcomes in Women Are Conceived Through Assisted Reproductive Technology Compared to Other Fertility Treatments and Naturally Conceived Women: It is a Retrospective Cohort Study Conducted Over a 5-year Period at a Fertility Center in a Lebanese Hospital
Background: The number of couples experiencing difficulties conceiving and seeking treatment for infertility has increased dramatically over time.
- Conditions
- Preterm Birth, Gestational Diabetes Mellitus (GDM), Gestational Hypertension
- Trial name
- non (NCT06836843)
- Testing
- Since this is an observational study rather than an interventional study, the exposure type refers to all potential factors influencing pregnancy both before and during pregnancy
- Where
- Lebanon
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Lebanese University
Chronic Myeloproliferative Disorders, Leukemia
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients with stage III or stage…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002980
- Testing
- decitabine
- Where
- 4 sites in United States
- Sponsor
- California Cancer Consortium
Iron Deficiency Anemia
Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA
Iron Deficiency Anemia (IDA) is a prevalent global health issue affecting a significant proportion of the population, including children.
- Trial name
- NCT06550362
- Testing
- iron sulfate
- Volunteers
- 100 people
- Sponsor
- Loma Linda University
Obesity, Ketogenic Dieting
Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar or Schizophrenia Illness
To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with either schizophrenia or bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or…
- Conditions
- Obesity, Ketogenic Dieting, Metabolic Syndrome, Bipolar Disorder
- Trial name
- NCT03935854
- Testing
- LCHF, Ketogenic Diet
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Type 2 Diabetes
Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)
This observational retrospective study will describe characteristics of patients with type 2 diabetes mellitus (T2DM) who were initiating use or treatment with sodium-glucose co-transporter-2 (SGLT-2) inhibitors and other…
- Trial name
- NCT03694470
- Where
- Russia
- Volunteers
- 10,000 people
- Sponsor
- AstraZeneca